AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03607149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)
Study NCT02244619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Description: Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
Study NCT02244619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
Study NCT04561284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indigestible fiber (classified)
Description: Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
Study NCT04561284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
Study NCT05469152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD
Description: Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.
Study NCT02866318 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Study NCT03426449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral sphincterotomy
Description: Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
Study NCT03426449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral sphincterotomy
Description: Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
Study NCT03971292 — intervention group
Intervention type: GENETIC
Intervention: RNA sequencing
Description: Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
Study NCT02377076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation
Description: Dietary calcium supplementation as milk powder
Study NCT02377076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control (Whey protein, vitamin D, sugar and salt)
Study NCT03134469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Description: Probiotic supplement
Study NCT03134469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement
Study NCT02974660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine sulfate
Study NCT02974660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study NCT02614261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT02530658 — intervention group
Intervention type: OTHER
Intervention: Informed Consent Follow-Up Visit
Description: At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
Study NCT02530658 — intervention group
Intervention type: OTHER
Intervention: Return of Results Conversation
Description: Participants will complete the assessment questionnaires.
Study NCT02530658 — intervention group
Intervention type: OTHER
Intervention: Return of Results Follow-Up Visits
Description: Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
Study NCT02614261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galcanezumab
Description: Administered SC
Study NCT02614261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02530658 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
Study NCT02530658 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
Study NCT02180178 — intervention group
Intervention type: OTHER
Intervention: observational only- no intervention
Study NCT04043130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulse
Description: The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
Study NCT04043130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulse
Description: The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
Study NCT00517127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
Study NCT00517127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethylstarch 6% 130/0.4
Description: Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
Study NCT00401986 — intervention group
Intervention type: DEVICE
Intervention: Bronchial thermoplasty with the Alair System
Description: Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
Study NCT00045188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00045188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT02252991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Description: Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
Study NCT00552578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
Study NCT00552578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
Study NCT03851367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gym ball exercises
Description: 3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
Study NCT03343184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEE Strategy and Incremental Restoration
Description: 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
Study NCT03343184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SEE Strategy and Bulk Fill Restoration
Description: 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
Study NCT03343184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SET Strategy and Incremental Restoration
Description: no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
Study NCT03343184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SET Strategy and Bulk Fill Restoration
Description: no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
Study NCT03555175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eccentric exercise
Description: The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
Study NCT03555175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proprioception
Description: The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
Study NCT03555175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Any exercise
Study NCT02837211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tapered Low Calorie Diet
Description: All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period.
Study NCT02837211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Low-Calorie Diet
Description: All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level.
Study NCT01645566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)
Study NCT02080169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
Study NCT04129203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versi Retriever thrombectomy
Description: Mechanical thrombectomy using Versi Retriever
Study NCT01243814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronate intra-articular injection
Description: joint injection in ankle with hyaluronate
Study NCT02080169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.
Study NCT02080169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
Study NCT02131961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase ointment
Description: 250 collagenase units/g
Study NCT02131961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Contact Cast System
Description: 1 Unit
Study NCT01671332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV over 60 minutes, 75 mg/m2
Study NCT01671332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: IV over 30 minutes
Study NCT01671332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV over 60 minutes. 56 mg/m2
Study NCT04058249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta-burst stimulation over right DLPFC
Description: All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator.
Study NCT03283319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 ug Panblok H7
Description: 0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
Study NCT03283319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
Study NCT03283319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 ug Panblok H7
Description: Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
Study NCT01243814 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: joint injection with saline solution for placebo
Study NCT03283319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59
Description: 0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
Study NCT03283319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS03
Description: 0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
Study NCT02828241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-04 Ointment
Study NCT02828241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Study NCT01135186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sapropterin dihydrochloride
Description: sapropterin dihydrochloride: 10mg/kg/day
Study NCT04674865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Physical therapy protocol
Description: Standardized Phase 1 protocol without for 7 days without ANB sessions.
Study NCT04674865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate nostrils breathing
Description: Alternate nostrils breathing 2 sessions per day
Study NCT00996138 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
Description: High dose group and low dose group of adjuvanted vaccines
Study NCT00822406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: homeopathic medicine
Description: individualized homeopathic medicine
Study NCT00822406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: homeopathic medicine
Description: individualized homeopathic medicine
Study NCT00822406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - 6 months
Study NCT04023162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Activity
Description: Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
Study NCT04023162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Therapy Exercise
Description: Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
Study NCT04023162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
Study NCT01405716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: 8-week mindfulness based program will be compared to and education control group
Study NCT01405716 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 8-week health education program
Study NCT00132028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00132028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01717716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with Sucralose
Study NCT01717716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with HFCS
Study NCT01717716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water with glucose